A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 761 in Subjects With Asthma
Phase of Trial: Phase I
Latest Information Update: 11 Jun 2014
At a glance
- Drugs Mogamulizumab (Primary)
- Indications Asthma
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Amgen
- 10 Jun 2017 Biomarkers information updated
- 11 Jun 2014 Status changed from active, no longer recruiting to discontinued.
- 10 Jan 2014 Planned End Date changed from 1 May 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov record.